Page 177 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

156 PART II Diagnostic Procedures for the Cancer Patient

10. Shapiro SG, Raghunath S, Williams C, et al.: Canine urothelial car- 33. Moore PF, Rodriguez-Bertos A, Kass PH: Feline gastrointestinal
cinoma: genomically aberrant and comparatively relevant, Chromo- lymphoma: mucosal architecture, immunophenotype, and molecu-
some Res 23:311–331, 2015. lar clonality, Vet Pathol 49:658–668, 2012.
VetBooks.ir 11. Mochizuki H, Shapiro SG, Breen M: Detection of copy number 34. Sabattini S, Lopparelli RM, Rigillo A, et al.: Canine splenic nodular
lymphoid lesions: immunophenotyping, proliferative activity and
imbalance in canine urothelial carcinoma with droplet digital poly-
merase chain reaction, Vet Pathol 53:764–772, 2016.
clonality assessment, Vet Pathol 55:645–653, 2018.
12. Hoeppner MP, Lundquist A, Pirun M, et al.: An improved canine 35. Stokol T, Nickerson GA, Shuman M, et al.: Dogs with acute myeloid
genome and a comprehensive catalogue of coding genes and non- leukemia have clonal rearrangements in T and B cell receptors, Front
coding transcripts, PLoS One 9:e91172, 2014. Vet Sci 4:76, 2017.
13. Montague MJ, Li G, Gandolfi B, et al.: Comparative analysis of 36. Avery PR, Burton J, Bromberek JL, et al.: Flow cytometric charac-
the domestic cat genome reveals genetic signatures underlying feline terization and clinical outcome of CD4+ T-cell lymphoma in dogs:
biology and domestication, Proc Natl Acad Sci U S A 111:17230– 67 cases, J Vet Intern Med 28:538–546, 2014.
17235, 2014. 37. Flood-Knapik KE, Durham AC, Gregor TP, et al.: Clinical, histo-
14. Letard S, Yang Y, Hanssens K, et al.: Gain-of-function mutations pathological and immunohistochemical characterization of canine
in the extracellular domain of KIT are common in canine mast cell indolent lymphoma, Vet Comp Oncol 11:272–286, 2013.
tumors, Mol Cancer Res 6:1137–1145, 2008. 38. Sato M, Yamazaki J, Goto-Koshino Y, et al.: Evaluation of cyto-
15. Takeuchi Y, Fujino Y, Watanabe M, et al.: Validation of the prog- reductive efficacy of vincristine, cyclophosphamide, and doxorubi-
nostic value of histopathological grading or c-kit mutation in canine cin in dogs with lymphoma by measuring the number of neoplastic
cutaneous mast cell tumours: a retrospective cohort study, Vet J lymphoid cells with real-time polymerase chain reaction, J Vet Intern
196:492–498, 2013. Med 25:285–291, 2011.
16. Weishaar KM, Ehrhart EJ, Avery AC, et al.: c-Kit mutation and 39. Mochizuki H, Goto-Koshino Y, Takahashi M, et al.: X-chromosome
localization status as response predictors in mast cell tumors in dogs inactivation pattern analysis for the assessment of cell clonality in
treated with prednisone and toceranib or vinblastine, J Vet Intern cats, Vet Pathol 49:963–970, 2012.
Med 32:394–405, 2018. 40. Mochizuki H, Goto-Koshino Y, Takahashi M, et al.: Demonstration
17. Suter SE, Small GW, Seiser EL, et al.: FLT3 mutations in canine of the cell clonality in canine hematopoietic tumors by X-chromo-
acute lymphocytic leukemia, BMC Cancer 11:38, 2011. some inactivation pattern analysis, Vet Pathol 52:61–69, 2015.
18. Decker B, Parker HG, Dhawan D, et al.: Homologous mutation 41. Delcour NM, Klopfleisch R, Gruber AD, et al.: Canine cutaneous
to human BRAF V600E is common in naturally occurring canine histiocytomas are clonal lesions as defined by X-linked clonality test-
bladder cancer - evidence for a relevant model system and urine- ing, J Comp Pathol 149:192–198, 2013.
based diagnostic test, Mol Cancer Res 13:993–1002, 2015. 42. Wong ML, Medrano JF: Real-time PCR for mRNA quantitation,
19. Holderfield M, Deuker MM, McCormick F, et al.: Targeting RAF Biotechniques 39:75–85, 2005.
kinases for cancer therapy: BRAF-mutated melanoma and beyond, 43. Quan PL, Sauzade M, Brouzes E: dPCR: a technology review, Sen-
Nat Rev Cancer 14:455–467, 2014. sors (Basel) 18:E1271, 2018.
20. Mochizuki H, Shapiro SG, Breen M: Detection of BRAF mutation 44. Schwarz JK, Payton JE, Rashmi R, et al.: Pathway-specific analysis
in uring DNA as a molecular diagnostic for canine urothelial and of gene expression data identifies the PI3K/Akt pathway as a novel
prostatic carcinoma, PLoS One 10:e0144170, 2015. therapeutic target in cervical cancer, Clin Cancer Res 18:1464–1471,
21. Wong S, Witte ON: The BCR-ABL story: bench to bedside and 2012.
back, Annu Rev Immunol 22:247–306, 2004. 45. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of dif-
22. Osumi K, Fukui T, Kiyoi H, et al.: Rapid screening of leukemia fuse large B-cell lymphoma identified by gene expression profiling,
fusion transcripts in acute leukemia by real-time PCR, Leuk Lym- Nature 403:503–511, 2000.
phoma 43:2291–2299, 2002. 46. Aresu L, Ferraresso S, Marconato L, et al.: New molecular and
23. Ulve R, Rault M, Bahin M, et al.: Discovery of human-similar gene therapeutic insights into canine diffuse large B cell lymphoma
fusions in canine cancers, Cancer Res 77:5721–5727, 2017. elucidates the role of the dog as a model for human disease, Hae-
24. Blom B, Spits H: Development of human lymphoid cells, Annu Rev matologica, 2018; epub ahead of print. https://doi.org/10.3324/hae-
Immunol 24:287–320, 2006. matol.2018.207027.
25. Delves PJ, Roitt IM: The immune system. First of two parts, N Engl 47. Richards KL, Motsinger-Reif AA, Chen HW, et al.: Gene profiling
J Med 343:37–49, 2000. of canine B-cell lymphoma reveals germinal center and postgermi-
26. Swerdlow SH: Genetic and molecular genetic studies in the diagno- nal center subtypes with different survival times, modeling human
sis of atypical lymphoid hyperplasias versus lymphoma, Hum Pathol DLBCL, Cancer Res 73:5029–5039, 2013.
34:346–351, 2003. 48. Dave SS, Wright G, Tan B, et al.: Prediction of survival in follicu-
27. Keller SM, Vernau W, Moore PF: Clonality testing in veterinary lar lymphoma based on molecular features of tumor-infiltrating
medicine: a review with diagnostic guidelines, Vet Pathol 53:711– immune cells, N Engl J Med 351:2159–2169, 2004.
725, 2016. 49. Lenz G, Wright G, Dave SS, et al.: Stromal gene signatures in large-
28. Burnett RC, Vernau W, Modiano JF, et al.: Diagnosis of canine B-cell lymphomas, N Engl J Med 359:2313–2323, 2008.
lymphoid neoplasia using clonal rearrangements of antigen receptor 50. Rimsza LM, Roberts RA, Miller TP, et al.: Loss of MHC class II
genes, Vet Pathol 40:32–41, 2003. gene and protein expression in diffuse large B-cell lymphoma is
29. Burnett RC, Blake MK, Thompson LJ, et al.: Evolution of a B-cell related to decreased tumor immunosurveillance and poor patient
lymphoma to multiple myeloma after chemotherapy, J Vet Intern survival regardless of other prognostic factors: a follow-up study
Med 18:768–771, 2004. from the Leukemia and Lymphoma Molecular Profiling Project,
30. Lane J, Price J, Moore A, et al.: Low-grade gastrointestinal lymphoma in Blood 103:4251–4258, 2004.
dogs: 20 cases (2010 to 2016), J Small Anim Pract 59:147–153, 2018. 51. Bumgarner R: Overview of DNA microarrays: types, applications,
31. Ohmura S, Leipig M, Schopper I, et al.: Detection of monoclonality and their future, Curr Protoc Mol Biol Chapter 22, 2013. Unit 22 21.
in intestinal lymphoma with polymerase chain reaction for antigen 52. Wang Z, Gerstein M, Snyder M: RNA-Seq: a revolutionary tool for
receptor gene rearrangement analysis to differentiate from enteritis transcriptomics, Nat Rev Genet 10:57–63, 2009.
in dogs, Vet Comp Oncol 15:194–207, 2017. 53. Hanahan D, Weinberg RA: Hallmarks of cancer: the next genera-
32. Gress V, Wolfesberger B, Fuchs-Baumgartinger A, et al.: Character- tion, Cell 144:646–674, 2011.
ization of the T-cell receptor gamma chain gene rearrangements as 54. Zhang MH, Man HT, Zhao XD, et al.: Estrogen receptor-posi-
an adjunct tool in the diagnosis of T-cell lymphomas in the gastroin- tive breast cancer molecular signatures and therapeutic potentials
testinal tract of cats, Res Vet Sci 107:261–266, 2016. (Review), Biomed Rep 2:41–52, 2014.